Multicentric Castleman Disease (MCD)
A rare systemic disorder involving enlarged lymph nodes in multiple regions of the body, driven by excess inflammatory signaling.
- Multiple Lymph Node Regions Involved
- HHV8-Associated or Idiopathic
- Systemic Inflammatory Symptoms
- Most Common In
- Adults; HIV+ individuals at higher risk for HHV8 subtype
- Primary Site
- Multiple Lymph Node Regions
- Disease Behavior
- Systemic, Chronic or Relapsing
- Advanced Therapies
- IL-6 Targeted Therapy, Clinical Trials
Condition Overview
Multicentric Castleman Disease (MCD) is a rare disorder in which lymph nodes in multiple regions of the body become enlarged due to abnormal overgrowth of cells and excessive inflammatory signaling, particularly interleukin-6 (IL-6). Unlike unicentric Castleman disease, which affects a single lymph node region, MCD is systemic and can cause widespread symptoms.
Types and Subtypes
Multicentric Castleman Disease is classified based on the presence or absence of human herpesvirus-8 (HHV8) infection.
Symptoms and Signs
MCD typically causes systemic symptoms related to widespread inflammation, in addition to enlarged lymph nodes.
Causes and Risk Factors
The cause of MCD differs by subtype, with HHV8 infection driving one form and immune dysregulation underlying the idiopathic form.
Diagnosis and Investigations
Diagnosing MCD requires a combination of lymph node biopsy, laboratory testing, and imaging to confirm the diagnosis and exclude other causes of lymphadenopathy.
Staging and Risk Groups
MCD is not staged like a typical cancer but is categorized by disease severity, which helps guide treatment intensity.
Standard Treatment
Treatment of MCD depends on the underlying subtype, with antiviral and immune-based therapies used for HHV8-associated disease and IL-6 targeted therapy as a mainstay for idiopathic MCD.
Advanced & Emerging Therapies
Patients with refractory or severe MCD may benefit from exploring newer targeted agents and clinical trials.
Targeted Therapy
IL-6/IL-6 Receptor Inhibitors
Directly target the inflammatory pathway driving idiopathic MCD.
Immunotherapy
Anti-CD20 Therapy (Rituximab-Based)
Used particularly in HHV8-associated MCD to target the underlying B-cell population.
Investigational Agents
JAK Inhibitors and Other Novel Agents
Being studied for refractory iMCD in clinical trials.
International Access
China-Based Specialist Centers
Patients may explore access to centers internationally with experience in rare lymphoproliferative disorders.
Biomarkers & Precision Medicine
Laboratory markers play a key role in diagnosing MCD, assessing severity, and guiding therapy selection.
When to Seek 2nd Opinion
Because MCD is rare and can be confused with lymphoma or other autoimmune conditions, a specialist second opinion can be important at key decision points.
Clinical Trials & Research
Prognosis & Outcomes
Outcomes in MCD vary depending on subtype, disease severity at diagnosis, and response to targeted therapy. Many patients achieve good disease control with appropriate treatment, though some experience a relapsing or chronic course.
Supportive Care
Supportive care addresses the systemic effects of MCD and helps manage treatment-related side effects.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Multicentric Castleman Disease access specialist review of pathology and lab results, connect with experienced centers, and explore IL-6 targeted therapy and clinical trial options.
Get a free case reviewFrequently Asked Questions
Multicentric Castleman Disease (MCD) is a rare disorder causing enlarged lymph nodes in multiple body regions, driven by excess inflammatory signaling such as IL-6.
Unicentric Castleman disease involves a single lymph node region and is often curable with surgery, while multicentric disease involves multiple regions and requires systemic treatment.
MCD can be caused by HHV8 (KSHV) infection, particularly in people who are HIV-positive, or it can occur without an identifiable infectious cause, known as idiopathic MCD (iMCD).
TAFRO is a severe subtype of idiopathic MCD characterized by Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis, and Organomegaly, often requiring urgent treatment.
Diagnosis requires a lymph node biopsy combined with laboratory testing, HHV8/HIV status, and imaging to assess the extent of disease.
Treatment depends on subtype: IL-6 targeted therapy is the mainstay for idiopathic MCD, while antiviral and rituximab-based therapy are often used for HHV8-associated MCD.
Many patients achieve good long-term disease control with treatment, though MCD can follow a chronic or relapsing course requiring ongoing management.
MCD is a lymphoproliferative disorder rather than a classic cancer, but it shares some features with lymphoma and is managed by hematology-oncology specialists.
Yes. CancerFax can help review medical reports, coordinate second opinions with specialists experienced in Castleman disease, and explore targeted therapy and clinical trial access, including international coordination.
Have a Castleman Disease Diagnosis?
Send your medical reports to CancerFax for review and explore second opinion and advanced therapy options.